Silymarin vs Hesperidin/Diosmin in Fibromyalgia

Inclusion Criteria: * Informed written consent. * Participant must meet the American College of Rheumatology 2016 revised classification criteria for Fibromyalgia: Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5, or WPI 3 to 6 and SS scale score ≥ 9 * Age \>18 years old (males and females) * Diagnosis of FM confirmed by a rheumatologist. * Persistent pain syndrome on conventional therapy. * Not taking Daflon or Legalon for 6 months. Exclusion Criteria: * Pain due to other conditions (e.g. diabetic peripheral neuropathic pain or post-herpetic neuralgia) that would confound assessment or self-evaluation of the pain associated with FM. * Patients with pain due to any widespread inflammatory musculoskeletal disorder (e.g. rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM. * Allergy to silymarin or diosmin or hesperidin. * Cognitive deficits that could impair understanding of the study, completion of questionnaires, or adherence to therapy. * Pregnant or planning pregnancy women and breastfeeding women. * Major comorbidities like renal impairment, severe liver disease, chronic hepatitis C, history of alcohol or drug addiction. * Current severe or uncontrolled major depressive disorder or anxiety disorders. * Patients will be excluded if there is no compliance to the medication.